EMA Publishes Annual Report - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

EMA Publishes Annual Report


The European Medicines Agency (EMA) released its annual report detailing drug approvals and agency projects completed in 2013, as well as initiatives started in the past year. According to the report, EMA recommended 81 drugs for marketing authorization in 2013, up from 57 in 2012. There was also an increase in the number of drugs containing new active substance; however, the number of generic drugs remained stable. EMA also recommended two new advance-therapy drugs in 2013 and approved 11 orphan drugs.

The report also highlights projects, initiatives, and achievements made by the agency in 2013 including access to clinical trial data as part of a marketing authorization application, advancement in patient access to medicine, reorganization of the agency, and implementation of new legislation. The report also details the agency’s pharmacovigilance activities as part of implementation of the European Union’s pharmacovigilance legislation.

Source: European Medicines Agency

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes

Click here